NCT04432025

Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Imperial College London · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.

Conditions

• Obesity
• Type 2 Diabetes

Interventions

Type	Name	Description
PROCEDURE	Bariatric surgery + goal directed medical therapy	Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
PROCEDURE	Bariatric surgery	Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner

Timeline

• Start date: 2021-04-01
• Primary completion: 2027-04-01
• Completion: 2027-08-01
• First posted: 2020-06-16
• Last updated: 2022-08-08

Locations

1 site across 1 country: Ireland